Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib in Adult Patients With Primary Immune Thrombocytopenia
NCT07196163Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in primary immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07196163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196163.